Receptor 2 za epidermalni rastni faktor (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Receptor 2 za epidermalni rastni faktor" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

4^th place

8^th place

2^nd place

5^th place

low place

34^th place

6^th place

9^th place

archive.org

Hayes DF, Lippman ME (2018). »Chapter 75: Breast Cancer«. V Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J (ur.). Harrison's Principles of Internal Medicine (20th izd.). McGraw-Hill Education. ISBN 978-1-259-64403-0.

Mitri Z, Constantine T, O'Regan R (2012). »The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy«. Chemotherapy Research and Practice. 2012: 743193. doi:10.1155/2012/743193. PMC 3539433. PMID 23320171.
Roy V, Perez EA (november 2009). »Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer«. The Oncologist. 14 (11): 1061–1069. doi:10.1634/theoncologist.2009-0142. PMID 19887469.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Mates M, Fletcher GG, Freedman OC, Eisen A, Gandhi S, Trudeau ME, Dent SF (Marec 2015). »Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline«. Current Oncology. 22 (Suppl 1): S114-22. doi:10.3747/co.22.2322. PMC 4381787. PMID 25848335.

Mitri Z, Constantine T, O'Regan R (2012). »The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy«. Chemotherapy Research and Practice. 2012: 743193. doi:10.1155/2012/743193. PMC 3539433. PMID 23320171.
Roy V, Perez EA (november 2009). »Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer«. The Oncologist. 14 (11): 1061–1069. doi:10.1634/theoncologist.2009-0142. PMID 19887469.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Mates M, Fletcher GG, Freedman OC, Eisen A, Gandhi S, Trudeau ME, Dent SF (Marec 2015). »Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline«. Current Oncology. 22 (Suppl 1): S114-22. doi:10.3747/co.22.2322. PMC 4381787. PMID 25848335.